The RFK ‘Wild’ Card: Uncertainty For US FDA In A Second Trump Term

 
• By Michael McCaughan

Republican presidential candidate Donald Trump says he will let Robert F. Kennedy Jr. “go wild on medicines” if he wins the White House. That could spell challenges for the US FDA in 2025.

No matter the role Kennedy is given in a potential Trump Administration, he could be a wild card for the FDA and its ability to operate. (Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Elections

More from Agency Leadership